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Abstract 
Background: The use of primaquine (PQ) for radical treatment of Plasmodium vivax in carriers of G6PD deficiency 
(G6PDd) constitutes the main factor associated with severe haemolysis in G6PDd. The current study aimed to estimate 
the incremental cost-effectiveness ratio of using a rapid diagnostic test (RDT) to detect G6PDd in male patients with P. 
vivax malaria in the Brazilian Amazon, in comparison with the routine indicated by the Programme for Malaria Control, 
which does not include this evaluation.
Methods: A cost-effectiveness analysis of estimated RDT use was carried out for the Brazilian Amazon for the year 
2013, considering the perspective of the Brazilian Public Health System. Using decision trees, estimates were com-
pared for two different RDT strategies for G6PDd in male individuals infected with P. vivax before being prescribed PQ, 
with the routine indicated in Brazil, which does not include prior diagnosis of G6PDd. The first strategy considered the 
combined use of RDT BinaxNOW® G6PD (BX-G6PD) in municipalities with more than 100,000 inhabitants and the rou-
tine programme (RP) for the other municipalities. Operational limitations related to the required temperature control 
and venous blood collection currently restrict the use of RDT BX-G6PD in small municipalities. The second strategy 
considered the use of the RDT CareStart™ G6PD (CS-G6PD) in 100 % of the municipalities. The analysis was carried out 
for the outcomes: “adequately diagnosed case” and “hospitalization avoided”.
Results: For the outcome “adequately diagnosed case”, comparing the RDT strategies based on RDT with the routine 
control programme (RP), the CS-G6PD strategy was the most cost-effective, with BX-G6PD extendedly dominating 
(the ICER of BX-G6PD compared with RP was higher than the ICER of CS-G6PD compared with RP). CS-G6PD domi-
nated the other strategies for the “hospitalization avoided” outcome.
Conclusion: The CS-G6PD strategy is cost-effective for adequately diagnosing cases and avoiding hospitalization. 
This information can help in decision-making, both in incorporating prior diagnosis in the use of PQ and to promote 
greater safety among G6PD deficient individuals in the Brazilian Amazon P. vivax endemic areas.
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Background
The use of primaquine (PQ) for radical treatment of Plas-
modium vivax in carriers of G6PD deficiency (G6PDd) 
constitutes the main factor associated with severe hae-
molysis, hospitalization and death in G6PDd individu-
als in Latin America, especially in males; cases of severe 
adverse events in females induced by PQ, have not been 
reported in the Brazilian Amazon [1, 2]. In Brazil, PQ 
is administered to prevent relapses of P. vivax malaria 
and to reduce its transmission [3]. However, this radical 
cure treatment of P. vivax malaria with PQ represents 
a risk for G6PDd carriers, since the Brazilian malaria 
national control programme does not recommend a 
routine G6PDd diagnosis before treatment starts. More 
than 99 % of the 178,600 new Brazilian cases of malaria 
in 2013 were reported in the Amazon, of which 81  % 
were caused by P. vivax [4, 5]. The estimates are approxi-
mately 6000 hospitalizations per year for individuals with 
G6PDd as a result of using PQ, creating a substantial bur-
den, of an estimated costing of US$ 4,858,108.87 per year, 
for the Brazilian Public Health Service (Sistema Único de 
Saúde/SUS) [6]. In this context, detecting G6PDd before 
PQ is prescribed could contribute to improving treat-
ment safety in people with G6PDd, preventing harm 
done to the efforts to control and eliminate malaria. In 
Brazilian Amazon, the prevalence of G6PDd in males was 
estimated at 4.5 % [7]. The identification and implemen-
tation of a rapid, efficient and feasible diagnostic method 
in field conditions is a priority [8–11].
The gold standard G6PDd diagnostic test is a quanti-
tative spectrophotometric assay that requires laboratory 
setting, complex equipment and specialized staff. In less 
sophisticated settings, the fluorescent spot test has been 
widely recommended because it is easy to execute. How-
ever, this test also requires specialized equipment, such 
as an ultraviolet bulb, a water bath and a micropipette. 
Thus, neither of these two tests can be considered appro-
priate for field conditions in most of the malarial areas in 
the Amazon region [8, 12–14], and they are not used in 
routine services.
Two RDTs have been evaluated to detect G6PDd in 
field conditions under different situations: BinaxNOW® 
G6PD (BX-G6PD) and CareStart™ G6PD (CS-G6PD). 
Both are qualitative chromatographic tests that are easily 
read visually, require minimal training and results can be 
obtained within 10 min [12, 15, 16].
BX-G6PD presents operational limitations related to 
temperature, as it provides reliable results only when 
performed at 18–25  °C range, and the sample required 
is venous blood [15, 17]. A recently reported multicentre 
study that included the city of Manaus found a sensitivity 
of 54.6 % and a specificity of 100 % for this test in malaria 
patients using a cut-off value corresponding to 60  % of 
normal activity [16]. The authors mentioned unpublished 
data for a cut-off of 40 % of normal activity the sensitivity 
and specificity were, respectively, 66.6 and 100 %.
CS-G6PD requires capillary blood samples collected 
from sterile finger pricks and results are not affected by 
high temperatures during its conservation and execution 
[12]. When this test was used for patients with malaria in 
Manaus, sensitivity was 45.45 % and specificity 98.71 %, 
for a cut-off value of 40  % of normal enzyme activity 
(Brito et al, Personal communication, 2015). In the gen-
eral population of villages in Cambodia, this cut-off value 
the test showed a sensitivity and specificity of 93.3 and 
97.4 % respectively [18].
The absence of cost-effectiveness analysis comparing 
the use of RDTs for G6PDd diagnosis with the status quo, 
where testing before PQ prescription is not performed, 
is an important gap that makes it difficult to recom-
mend these tests [13, 14, 19]. The absence of a G6PDd 
diagnosis also represents an obstacle for the future use 
of tafenoquine, a new promising 8-aminoquinoline that 
has shown high efficacy in radical cure of P. vivax malaria 
when administered as a single dose [6, 19, 20]. Therefore, 
the present cost-effectiveness study was carried out with 
the objective of estimating the incremental cost-effective-
ness ratio (ICER) of introducing a RDT to detect G6PDd 
in male patients carrying P. vivax in the Brazilian Ama-
zon, in comparison with the routine programme (RP) of 
the Brazil’s Malaria Control Programme.
Methods
A cost-effectiveness analysis (CEA) was done from the 
perspective of the Brazilian Public Health Service (SUS) 
for 2013. The study area covers the Brazilian Amazon, 
composed of 775 municipalities distributed in nine States 
(Acre, Amapá, Amazonas, Maranhão, Mato Grosso, 
Tocantins, Rondônia, Roraima and Pará), where the pop-
ulation is approximately 21 million, of whom 10 million 
live in 34 municipalities with more than 100,000 inhab-
itants [21]. In the region, 427 municipalities registered 
cases of P. vivax malaria in 2013 [4].
Two G6PDd RDT strategies were compared, in male 
individuals infected with P. vivax before they were pre-
scribed PQ, with the RP stipulated in Brazil, without 
prior diagnosis of G6PDd. Females were excluded since in 
Latin America clinically important manifestations occur 
mainly in males (cases of severe adverse events induced 
by PQ, have not been reported in the study region). The 
first strategy was based on the combined use of BX-G6PD 
in the municipalities with more than 100,000 inhabitants 
and the RP in other municipalities (BX-G6PD strategy). 
Operational limitations related to the required tempera-
ture control and venous blood collection restrict the use 
of RDT BX-G6PD in small municipalities. The second 
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was based on CS-G6PD (strategy CS-G6PD) consider-
ing its use in 100  % of the municipalities. The analysis 
was carried out for the outcomes: “adequately diagnosed 
case” and “hospitalization avoided”.
Assumptions
This analysis used the assumptions previously detailed 
by Peixoto et  al. [6], related to the diagnosis of malaria, 
the treatment of P. vivax and assistance to G6PDd carri-
ers with severe adverse events associated with PQ, except 
the cost of hospital staff. In the current study the total 
mean cost of the Authorization for Hospitalization (AIH) 
includes the payment of professional and hospital services 
done by SUS. It was also assumed that the diagnostic units 
were able to store and carry out tests at the temperature 
recommended by the manufacturers, and that the execu-
tion of CS-G6PD would be carried out by health agents 
and that of BX-G6PD by nursing technicians.
The decision model
Decision trees were used to compare the strategies being 
evaluated (Fig.  1). A hypothetical cohort was simulated 
from all male patients who presented fever and requested 
diagnosis for malaria, considering its various probabil-
ity nodes. After the malaria thick blood smear test, the 
patient was submitted to the probability of having or not 
having malaria, followed by the type of malaria—P. vivax 
or P. falciparum—and then to the probability of carry-
ing out a diagnosis with one of the RDTs for G6PDd or to 
the RP without G6PDd diagnosis. The individual infected 
with P. vivax might or might not carry the deficiency, and 
this estimate was based on the prevalence of G6PDd in 
the Amazon Region.
After carrying out one of the tests for G6PDd, the 
probabilities were taken relative to the sensitivity and 
specificity of the diagnostic strategy used, with true posi-
tives (TP), false positives (FP), true negatives (TN) and 
false negatives (FN) results. For RP, the model assumes 
that the strategy is not able to diagnose the G6PDd, since 
it does not uses diagnostic test for this purpose. After use 
of the diagnostic test, TP and TN results were considered 
adequately diagnosed cases, whereas FP and FN were 
considered incorrectly diagnosed cases. After diagnosis, 
the hypothetical cohort was analysed by the probability of 
hospitalization. It was assumed that all individuals clas-
sified as FN and TN were submitted to treatment with 
PQ, and those identified as TP and FP were not. Thus, 
the carrier of G6PDd who uses PQ (FN) is submitted to 
the probability of not being hospitalized (hospitalization 
avoided) or hospitalization due to severe adverse events 
provoked by the medication. All costs and epidemiologi-
cal parameters used in the decision model are shown in 
Tables 1 and 2.
Costs
For the outcome “adequately diagnosed case” the health 
costs arising from malaria diagnosis among male indi-
viduals and the diagnosis of G6PDd in individuals with 
P. vivax malaria were considered. For the outcome “hos-
pitalization avoided” medication-based treatment for P. 
vivax malaria and the costs of health assistance for those 
undergoing severe adverse events associated with the use 
of PQ in G6PDd carriers were added on (Table  1). The 
costs obtained in Brazilian currency (reais, R$) were con-
verted to US dollars (US$) using the mean value of the 
official exchange rate for the year 2013 (R$ 2.16 per dol-
lar) [22]. The costs identified in other years were adjusted 
based on the official inflation rates estimated by the accu-
mulated National Consumer Price Index (IPCA) [23].
Epidemiological parameters
Epidemiological data and those of services related to 
malaria and to G6PDd within the context of malaria were 
obtained from the Malaria Epidemiological Vigilance 
Information System (SIVEP/Malária) [4], from the sci-
entific literature and from unpublished documents and 
databanks at the Tropical Medicine Foundation Dr. Hei-
tor Vieira Dourado (FMT-HVD) (Table 2).
Cost‑effectiveness and sensitivity analysis
By means of the decision models, the final costs and the 
effectiveness of the strategies were obtained, as well as 
the incremental cost-effectiveness ratios (ICER) for “ade-
quately diagnosed case” and “hospitalization avoided”, 
considering the parameters used in base-case. Univariate 
and multivariate sensitivity analyses were carried out for 
all the epidemiological and cost parameters, except for 
the cost of the specialized medical consultation, which 
is a fixed cost in the health system and did not undergo 
alterations during the study period.
Tornado diagrams were based on the individual 
impact of each of the variables on the ICER to demon-
strate the results from univariate analysis. The probabil-
istic sensitivity analysis (PSA) was carried out by means 
of the second-order Monte Carlo simulation, which 
evaluated the simultaneous impact of all the mentioned 
variables with regard to ICER. The following distribu-
tions were attributed to the entry parameters: beta dis-
tribution for the probability parameters and gamma or 
triangular distribution for the cost parameters. Finally, 
considering the three strategies evaluated for each of 
the outcomes, 10,000 interactions were carried out 
to produce acceptability curves based on a willing-
ness to pay of US$ 6480 per additional outcome, which 
is equivalent to the per capita GDP for the Amazon 
Region. The software TreeAge Pro® 2013 (TreeAge Pro 
Inc, Williamstown, MA, USA) was used to construct the 
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decision model, for the calculation of the ICERs and for 
sensitivity analyses.
Ethical considerations
The research project was submitted to the Ethics Com-
mittee of the Faculty of Health Sciences at the University 
of Brasilia and approved on May 14th 2013 (case number 
276,522).
Results
The strategy based on the use of CS-G6PD in 100  % of 
the population was more cost-effective when compared 
to RP and the strategy that combines BX-G6PD and RP 
(BX-G6PD strategy). The BX-G6PD strategy was extend-
edly dominated (the ICER of BX-G6PD compared 
with RP was higher than the ICER of CS-G6PD com-
pared with RP) and the strategy CS-G6PD was the most 
Fig. 1 Decision tree for the outcomes: adequately diagnosed case (A–B) and avoided hospitalization (A–C). Brazilian Amazon, 2013
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cost-effective for the outcome “adequately diagnosed 
case”. For “hospitalization avoided”, the RP and BX-G6PD 
strategies were dominated by the CS-G6PD strategy 
(Table 3).
The univariate sensitivity analyses for the outcome 
“adequately diagnosed case” showed that variations in 
the epidemiological and cost parameters did not have an 
important impact on the ICERs, whose greatest variation 
was only US$ 0.45. For “hospitalization avoided” the CS-
G6PD strategy remained dominant in relation to the BX-
G6PD and RP strategies, as evidenced by negative ICERs, 
supporting a greater effectiveness and lower cost for the 
CS-G6PD strategy. Exceptions occurred only in the sen-
sitivity analysis of the variables sensitivity of CS-G6PD 
and prevalence of G6PDd, with positive ICERs (Fig. 2).
Two acceptability curves were generated for the PSA 
(Fig.  3), for the outcomes “adequately diagnosed case” 
and “hospitalization avoided” respectively. For both 
curves, the strategy based on CS-G6PD presented a high 
probability of being cost-effective, at 10  % of the limit 
considered in the analysis.
Additionally, ICERs were estimated considering the 
highest (18.6  %) and the lowest (4.3  %) proportion of 
malaria in individuals submitted to the thick blood 
Table 1 Cost components and unit costs considered in the analytical model
Brazilian Amazon, 2013
a Costing previously detailed by Peixoto et al. [6]
b Therapeutic schemes: chloroquine for 3 days and PQ for 7 days (males without G6PDd); chloroquine for 3 days (males with G6PDd) and prevention of relapse with 
chloroquine weekly for 12 weeks (prophylactic treatment)
c Based on the cost of one training period per year per municipality for the diagnosis of malaria with RDT OptiMal® in the Brazilian Amazon
d Cost per test based on the average salary of Amazonas State in 2013
e Variation obtained from the minimum and maximum cost identified in the time series of prices of bank (BPS) within the Ministry of Health (MoH) in 2013
f Cost obtained through the analysis of 108 files from the Hospital Information System (SIH/SUS) of the Brazilian Amazon in 2013
Items Cost per patient (unit costs, US$) Sources base‑case/variations
Base‑case Variations
Diagnosis of P. vivax malária
 Thick blood smeara 1.31 0.27–2.00 [40] / [35]–[40]
 Microscopea 0.75 0.60–0.90 [41] /± 20 %
 Microscope maintenancea 0.06 0.05–0.07 [41] /± 20 %
 Health workersa 3.48 2.78–4.18 [42] /± 20 %
 Annual training (microscopist)a 5.67 4.54–6.80 [35] /± 20 %
Drug treatment for P. vivax (therapeutic scheme)
 Males without G6PDdb 0.23 0.18–0.28 [43] /± 20 %
 Males with G6PDdb 0.12 0.10–0.14 [43] /± 20 %
 Males with G6PDd/prophylactic treatmentb 0.28 0.22–0.34 [43] /± 20 %
G6PDd diagnosis
 Training (RDT)c 0.80 0.64–0.96 [35] /± 20 %
CS-G6PD
 Health workerd 1.74 1.39–2.09 [42] /± 20 %
 One test 1.50 1.20–1.80 [44, 45] /± 20 %
 Suppliese 0.10 0.08–0.12 [46] / [46]–[46]
BX-G6PD
 Health workerd 2.04 1.63–2.45 [42] /± 20 %
 One test 5.88 4.70–7.06 [47] /± 20 %
 Suppliese 1.09 0.87–1.31 [45, 46] / [46]–[46]
Assistance to carriers of G6PDd treated with PQ
 Pre-admission testsa 10.69 9.65–11.38 [4, 40] / [4, 40]
 Medical appointmentsa 4.63 – [48] /–
 Hospitalization (AIH)f 198.81 159.05–238.57 [49] /± 20 %
 Hospital fooda 68.72 54.98–82.46 [50] /± 20 %
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smear test among the States evaluated. The results dem-
onstrate that the CS-G6PD strategy continues to be 
the most cost-effective one for appropriate diagnosis of 
G6PDd, presenting for both proportions the same ICER 
as that identified in the base-case when compared to the 
RP. For the outcome “hospitalization avoided”, the CS-
G6PD strategy continued to dominate the others. The 
second analysis of additional sensitivity simulated the 
amplification of the use of BX-G6PD for the municipali-
ties with more than 50,000 inhabitants (where 40.9 % of 
the cases of P. vivax malaria in men occurred). Again, 
the results did not cause significant modifications in 
the ICERs, and the CS-G6PD strategy continued to be 
the most cost-effective for the outcome “adequately 
diagnosed case” and was dominant for “hospitalization 
avoided”.
Discussion
Although malaria continues to be one of the main pub-
lic health problems in the world, there have been some 
successful results from control efforts in recent years, 
leading some endemic regions to consider the possibility 
of malaria eliminating [24]. Tatem et al. showed that the 
Americas present great potential for elimination of Plas-
modium falciparum, as well as operational conditions 
for controlling P. vivax. In this context, for the regional 
efforts directed to eliminating malaria to be successful, 
the strategies directed to combating P. vivax have taken 
on an even greater importance [9, 25].
The elimination of P. vivax malaria will only be possible 
with the effective use of an 8-aminoquinoline for the rad-
ical treatment of latent P. vivax infections [13, 19]. How-
ever, as the use of this type of anti-malarials threatens the 
Table 2 Epidemiological parameters considered in the analytic models. Brazilian Amazon, 2013
a Parameter obtained from the analysis of the databanks from the nine States of the Brazilian Amazon
b Parameter obtained from follow-up of patients with G6PDd in FMT-HVD
c Proportion corresponding to individuals diagnosed with P. vivax malaria, residents of municipalities with more than 100,000 inhabitants
d The cutoff point: 40 % of the median enzyme activity in the sample
e The base-case and the variation considering data from Brazil and Peru
f Brito et al. Personal Communication, 2015
Parameter Base‑case Variations Sources base‑case/
variations
Proportion of malaria among febrile males seeking diagnosisa 0.0886 0.0881–0.0891 [4] /IC 95 %
Proportion of malaria cases due to P. vivax in male patientsa 0.835 0.833–0.837 [4] /IC 95 %
Prevalence of G6PDd in male patients 0.045 0.025–0.056 [7] /f ]–[7] IC 95 %
Proportion of males with G6PDd hospitalized after treatment with PQb 0.943 0.744–1 [39] /± 20 %
Proportion of the use of BX-G6PDc 0.184 0.182–0.187 [4, 21] /IC 95 %
Sensitivity of CS-G6PDd 0.455 0.213–0.720 f/IC 95 %
Specificity of CS-G6PDd 0.987 0.967–0.995 f/IC 95 %
Sensitivity of BX-G6PDd, e 0.667 0.301–0.921 [16] /IC 95 %
Specificity of BX-G6PDd, e 1 0.989–1 [16] /IC 95 %
Table 3 Results of the cost-effectiveness analysis of the strategies “RP”, “CS-G6PD” and “BX-G6PD”, according to the out-
comes assessed in the Brazilian Amazon, 2013
Strategy Effectiveness Incremental effectiveness Cost (US$) Incremental cost (US$) ICER (US$)
Outcome: adequately diagnosed case
 RP 0 – 11.270 – –
 BX-G6PD (vs. RP) 0.0135 0.0135 11.404 0.134 9.96
 CS-G6PD (vs. RP) 0.0716 0.0716 11.578 0.308 4.30
 CS-G6PD (vs. BX-G6PD) 0.0716 0.0581 11.578 0.174 2.99
Outcome: hospitalization avoided
 CS-G6PD 0.0723 – 12.078 – Dominant
 BX-G6PD (vs. CS-G6PD) 0.0712 −0.0010 12.200 0.122 Dominated
 RP (vs. CS-G6PD) 0.0708 −0.0014 12.175 0.097 Dominated
 BX-G6PD (vs. RP) 0.0712 0.0004 12.200 0.025 63.92
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safety of G6PDd individuals, previous diagnosis of this 
condition in patients with P. vivax malaria needs discus-
sion [13, 19], and it is vital that cost-effective diagnostic 
strategies are identified [1, 6, 11].
The RDTs considered in the study have different accu-
racies and integrate different strategies. The cost asso-
ciated with performing each test (training and salary of 
health workers, test kits and supplies) was also different: 
US$ 9.81 for BX-G6PD and US$ 4.14 for CS-G6PD.
The present study constitutes the first CEA of strategies 
based on the two main RDTs for diagnosing G6PDd that 
are available and feasible under field conditions. These 
were compared to the routine strategy for prescribing PQ 
without prior diagnosis of the deficiency in the Brazil-
ian Amazon. The results indicate that the strategy based 
on the use of CS-G6PD is cost-effective, for the outcome 
“adequately diagnosis of G6PDd”, whose ICERs were 
lower than 1 % of the per capita GDP of the region, and 
also for the outcome “hospitalization avoided”, for which 
it was dominant.
A hypothetical 2013 cohort of 1,188,523 males present-
ing with fever and requesting diagnosis for malaria would 
be administered 87,928 RDT CS-G6PD in males with P. 
vivax (RDT in 100 % of the municipalities) or 16,179 RDT 
BX-G6PD in males with P. vivax, based on combined use 
with RP (RDT in 18.4  % of the municipalities), which 
could prevent, respectively, 1808 hospitalizations (a cost 
of US$ 511,522) and 488 hospitalizations (US$ 137,974).
The analysis assumed the values of sensitivity and spec-
ificity obtained in studies carried out with patients diag-
nosed with malaria (Table 2). These estimate a reduction 
in the accuracy of the RDTs evaluated when compared 
Fig. 2 Univariate sensitivity analysis for the outcome hospitalization 
avoided, based on the individual impact of each of the variables on 
the ICER. Brazilian Amazon, 2013
Fig. 3 Acceptability curves of the three evaluated strategies in 
accordance with the outcome. Brazilian Amazon, 2013
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to the accuracy estimated in studies with the general 
population. This may occur due to the greater number of 
new erythrocytes produced as a result of the acute hae-
molysis provoked by malaria, since new erythrocytes 
present more G6PD enzymatic activity when compared 
to mature cells, which may lead to false negative results 
[16, 26].
A recent study that evaluated the new generation of 
CS-G6PD demonstrated an improvement in its sensitiv-
ity for the general population in Cambodia [18], which 
could also occur in individuals with malaria, making the 
strategy even more cost-effective. Corroborating these 
promising results, another study in an area with high 
incidence of malaria in Africa recently estimated 100  % 
sensitivity in the general male population [27].
When the uncertainties concerning epidemiological 
and cost parameters were tested by means of the univari-
ate analysis of sensitivity, the performance of the strategy 
based on CS-G6PD was not affected in an important way. 
The lowest variations in the sensitivity parameter of CS-
G6PD and the prevalence parameter of G6PDd altered 
the dominance relationship of the CS-G6PD strategy for 
the outcome “hospitalization avoided”, but the strategy 
remained cost-effective.
The acceptability curves indicate that the probability of 
the strategy based on CS-G6PD being cost-effective is of 
approximately 100 %, for both outcomes, at 10 % of the 
limit of willingness to pay. For the second outcome, when 
the willingness to pay is US$ 0.00, the probability is over 
90 %, demonstrating that the stochastic and simultaneous 
variation of the parameters for epidemiology and costs 
used indicates a high probability of the CS-G6PD strat-
egy being cost-effective, despite the uncertainties inher-
ent in the analytical model.
Decision-makers are being faced with increasingly dif-
ficult decisions when they consider the addition of new 
technologies to national malaria control program [28]. 
Aiming to help in decision-making, various economic 
studies have examined aspects related to primary preven-
tion, diagnosis and treatment of malaria, with emphasis 
on vaccines [29, 30], mosquito nets impregnated with 
insecticides [31, 32], mass screening followed by treat-
ment [33], use of RDTs to diagnose the infection [34, 35] 
and the use of schemes for chemo-prophylaxis and treat-
ment [36–38]. Although there are no published studies 
on cost-effectiveness for G6PDd diagnosis in connec-
tion with malaria, recent publications have discussed 
the urgency of evaluating the efficiency of RDTs used to 
detect G6PDd so as to guarantee safety in the treatment 
of these patients [11, 13, 14].
This study presents some limitations, such as the fact 
that some epidemiological and cost parameters arise 
from one Amazon state arguing that results can be 
extrapolated to Brazilian Amazon. However, in the analy-
sis of sensitivity, which includes plausible variations for 
the region studied, there were no important changes in 
the ICERs. The prevalence of G6PDd, the costs of hos-
pital food and the salaries of the professionals involved 
in the RDT were generalized from data on the State 
of Amazonas, and the proportions of hospitalizations 
(94.29  %) were calculated from a cohort of G6PDd car-
riers who were monitored at FMT-HVD [39]. This rep-
resents the situation at a center of excellence, differing 
from the context in small towns of the Brazilian Ama-
zon. Thus, the proportion of hospitalizations may have 
been overestimated, since in these places there is limited 
access to health services with moderate to high techno-
logical density [6].
Within this scope, the present study estimated a cost-
effectiveness ratio that is favorable to the use of RDTs for 
G6PDd in the Brazilian Amazon, in particular CS-G6PD. 
Decision-makers in the National Programme of Preven-
tion and Control of Malaria in the region should consider 
implementation of such RDT strategies for G6PDd diag-
nosis. The incorporation of RDTs will make the use of 
8-aminoquinolines safer and may represent an increase 
in the effectiveness of P. vivax malaria control in Brazil.
Conclusion
The strategy based on CS-G6PD is cost-effective in 
diagnosing G6PDd and avoiding hospitalization. These 
results may help in future decision-making related to the 
use of CS-G6PD in the Brazilian Amazon when consid-
ering a safer P. vivax malaria treatment in the region for 
G6PDd individuals.
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